MET and cancer: As QSP models of such kind have significant potential in terms of proposing and evaluating new combinations (Wang et al., 2023; Jafarnejad et al., 2019; Zhou et al., 2024), it is also of great interest to incorporate more therapeutics in addition to small molecule inhibitors but relevant for MET-aberrant cancers in the future versions of the model.